BOSTON SCIENTIFIC CORP (BSX) Form 10-Q — Nov 2, 2026
Boston Scientific's Q3 2026 results were materially hurt by a cybersecurity incident first reported August 26, 2026 that caused a global disruption to manufacturing and order fulfillment. Net sales rose just 1.5% to $5.138 billion while reported net income fell 22.9% year-over-year to $582 million ($0.40 diluted EPS vs $0.51 a year ago). Adjusted EPS was $0.73, down 2.6% from $0.75. The pending ~$14.5 billion ($374/share) acquisition of Penumbra remains on track but closing has shifted to early 2027, with both companies responding to an FTC Second Request issued in March 2026.
Key figures
- Eps
- 0.4
- Revenue
- 5138000000
- Net Income
- 582000000
- Revenue Yoy
- 1.5% (Q3); 6.7% nine months ($15.784B vs $14.788B)
- Total Assets
- 45461000000
- Cash Position
- 609000000
- Shares Outstanding
- 1449473222
- Asr amount busd
- 2
- Organic growth q3
- 1.5%
- Q3 eps prior year
- 0.51
- Legal accrual musd
- 370
- Ting SN upfront musd
- 250
- Scivita upfront musd
- 213
- Leverage ratio actual
- 1.95x vs 3.75x covenant max
- Mirus investment busd
- 1.6
- Mirus tavr option busd
- 3
- Ting SN milestones musd
- 75
- Penumbra deal value busd
- 14.5
- Penumbra price per share
- 374
- Nalu medical upfront musd
- 523
- Litigation charges q3 musd
- 81
- Nine month net income musd
- 2823
- Organic growth nine months
- 5.8%
- Blackstone funding cap musd
- 455
- Iprd impairment charge musd
- 39
- Q3 net income prior year musd
- 755
- Commercial paper outstanding musd
- 1029
- Buyback authorization remaining busd
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.